سعر الزيكسا 10 مجم 30 قرص 2024

Memantine hydrochloride 10 mg film-coated tablets, pack of 30 (3 strips); used for moderate to severe dementia of the Alzheimer's type.

• Treatment of moderate to severe dementia of the Alzheimer's typePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (≥5% and greater than placebo): dizziness, headache, confusion and constipation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to memantine hydrochloride or to any excipients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Conditions that raise urine pH (drugs such as carbonic anhydrase inhibitors or sodium bicarbonate, diet changes, renal tubular acidosis, severe urinary tract infection) may decrease urinary elimination of memantine and increase plasma levels (clearance reduced by about 80% at urine pH 8).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs that make urine alkaline (carbonic anhydrase inhibitors, sodium bicarbonate)May reduce memantine clearance and increase plasma levels.DailyMed (U.S. National Library of Medicine)
• Other NMDA antagonists (amantadine, ketamine, dextromethorphan)Combined use has not been systematically evaluated; use with caution.DailyMed (U.S. National Library of Medicine)

• There are no adequate data on developmental risk of memantine in pregnant women; in animal studies, adverse developmental effects (decreased body weight and skeletal ossification) occurred at or above clinically relevant doses.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• There are no data on the presence of memantine in human or animal milk, effects on the breastfed infant or milk production.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Memantine: Postulated to act as a low-to-moderate affinity uncompetitive (open-channel) NMDA receptor antagonist, reducing effects of persistent glutamatergic activation; no evidence that it prevents or slows neurodegeneration (US label).